The Department of Veterans Affairs, specifically the Network Contracting Office 23, intends to award a sole-source, fixed-price indefinite delivery contract for Afirma thyroid testing services to Veracyte, Inc. This contract will provide essential genomic and expression testing necessary for diagnosing thyroid cancer, utilizing minimally invasive methods to enhance patient care across various VA health care facilities in the Midwest region. The procurement process is guided by federal acquisition regulations, and while Veracyte, Inc. is currently the only authorized provider, other vendors are encouraged to submit capability statements by April 18, 2025, to determine the feasibility of competitive procurement. Interested parties may contact Contract Specialist Logan Gahring at logan.gahring@va.gov for further inquiries.